BION-1301 Treatment Results in Sustained, Clinically Meaningful Proteinuria Reductions BION-1301 treatment results in proteinuria reductions within 3 months, which are sustained and continue to ...
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results